Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index.

Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation

Open access

Abstract

There is a widespread acceptance in the literature that plasma nonesterified fatty acids (NEFA), also called free fatty acids (FFA), can mediate many adverse metabolic effects, most notably insulin resistance. Elevated NEFA concentrations in obesity are thought to arise from an increased adipose tissue mass. It is also argued that the process of fatty acid mobilization from adipose tissue, normally suppressed by insulin, itself becomes insulin resistant—thus, lipolysis is further increased, potentially leading to a vicious cycle. Although we have also accepted this model for many years (1,2), recently there has been a steady accumulation of data, both in the literature and from our own research, that has forced us to realize that this simple story is not always true. Here we review the background to the idea of “fatty acids as metabolic villains,” together with data from the literature and from our own studies, which tend to show another side to the fatty acids/insulin resistance story. We will first examine the relationship between systemic concentrations of NEFA and obesity/insulin resistance and then study adipose tissue in the obese state with regard to its adaptation for NEFA release. NEFA circulate in the plasma bound to plasma albumin. Their function was largely elucidated in the 1950s through the work of Vincent Dole (3) at the Rockefeller Institute in New York and Robert Gordon (4,5) at the National Institutes of Health. Gordon demonstrated the origin of plasma NEFA from adipose tissue and their use by tissues such as the liver and myocardium, but not the brain. We now recognize that NEFA are the vehicle by which triacylglycerol (TG) stored in adipose tissue is transported to its sites of utilization. NEFA turnover is rapid, with a plasma half-life around 2–4 min (6). The only significant site of NEFA liberation …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db11-0425

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Bubble graph representing the relationship between the difference in estimated fat mass and the difference in plasma NEFA concentration in 43 independent publications published 1990–2008 (Supplementary Table 1) between lean and overweight/obese subjects. Each bubble represents one study, and the bubble area is proportional to the number of observations (participants).
FIG. 1. Bubble graph representing the relationship between the difference in estimated fat mass and the difference in plasma NEFA concentration in 43 independent publications published 1990–2008 (Supplementary Table 1) between lean and overweight/obese subjects. Each bubble represents one study, and the bubble area is proportional to the number of observations (participants).CC BY-NC-ND · PubMed Central
FIG. 2. Relationships between plasma NEFA concentrations and BMI in two cohorts. Black bars, plasma NEFA concentrations; gray bars, fat mass. A: Data from the Paris Prospective Study (46), courtesy of Beverley Balkau, in 5,790 individuals. Fat mass has been estimated from BMI (61). B: Data from OBB for 1,591 individuals. In each case, the mean ± SE plasma NEFA concentration is shown for quintiles of BMI. The BMI quintiles were as follows: I: <22.5 kg/m2; II: 22.5–24.4 kg/m2; III: 24.4–26.4 kg/m2; IV: 26.4–29.2 kg/m2; V: >29.2 kg/m2.
FIG. 2. Relationships between plasma NEFA concentrations and BMI in two cohorts. Black bars, plasma NEFA concentrations; gray bars, fat mass. A: Data from the Paris Prospective Study (46), courtesy of Beverley Balkau, in 5,790 individuals. Fat mass has been estimated from BMI (61). B: Data from OBB for 1,591 individuals. In each case, the mean ± SE plasma NEFA concentration is shown for quintiles of BMI. The BMI quintiles were as follows: I: <22.5 kg/m2; II: 22.5–24.4 kg/m2; III: 24.4–26.4 kg/m2; IV: 26.4–29.2 kg/m2; V: >29.2 kg/m2.CC BY-NC-ND · PubMed Central
FIG. 3. Relationships between NEFA release from subcutaneous abdominal adipose tissue and fat mass (A) and fasting insulin (B) in different groups of subjects. The NEFA release has been quantified with the same technique in separate group of subjects from previous studies in our laboratory using arteriovenous concentration differences across abdominal subcutaneous tissue multiplied by the tissue blood flow. Only data from men are shown. Open circle, healthy lean control subjects; solid circle, healthy obese subjects (62). Solid square, lean control subjects (80). Upward triangle, lean control subjects (81). Cross, lean control subjects (82). Square with hour-glass fill: healthy control subjects aged 31–59 years, BMI 22–28 kg/m2 (K. Manolopoulos, unpublished data). Open star, control subjects for insulin resistance study; solid star, men with insulin resistance (83). Downward triangle, healthy obese men (12). Open diamond, type 2 diabetic patients on rosiglitazone; solid diamond, same patients on placebo (84). Note that the different groups of lean control subjects had different characteristics (age, BMI) as detailed in the individual publications. For each group, mean values ± SE are shown.
FIG. 3. Relationships between NEFA release from subcutaneous abdominal adipose tissue and fat mass (A) and fasting insulin (B) in different groups of subjects. The NEFA release has been quantified with the same technique in separate group of subjects from previous studies in our laboratory using arteriovenous concentration differences across abdominal subcutaneous tissue multiplied by the tissue blood flow. Only data from men are shown. Open circle, healthy lean control subjects; solid circle, healthy obese subjects (62). Solid square, lean control subjects (80). Upward triangle, lean control subjects (81). Cross, lean control subjects (82). Square with hour-glass fill: healthy control subjects aged 31–59 years, BMI 22–28 kg/m2 (K. Manolopoulos, unpublished data). Open star, control subjects for insulin resistance study; solid star, men with insulin resistance (83). Downward triangle, healthy obese men (12). Open diamond, type 2 diabetic patients on rosiglitazone; solid diamond, same patients on placebo (84). Note that the different groups of lean control subjects had different characteristics (age, BMI) as detailed in the individual publications. For each group, mean values ± SE are shown.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 896

Metadata

Authors
Karpe, F., Dickmann, J. R., & Frayn, K. N.
Affiliations
  • John Radcliffe Hospital (GB)
  • University of Oxford (GB)
Corresponding author
Karpe, Fredrik
Venue
Diabetes
Published
2011-09-16
Volume
60
Issue
10
Pages
2441-2449
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2152688545
Cited by
896
References
91
Citations by year
2026: 29 · 2025: 33 · 2024: 41 · 2023: 45 · 2022: 73 · 2021: 72 · 2020: 76 · 2019: 74 · 2018: 68 · 2017: 85 · 2016: 76 · 2015: 78 · 2014: 57 · 2013: 53 · 2012: 31
FWCI
5.40
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust
  • University of Oxford
  • Institut National de la Santé et de la Recherche Médicale
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
free fatty acids, obesity, insulin resistance, adipose tissue lipolysis, fatty acid mobilization, plasma albumin binding, triacylglycerol mobilization, insulin signaling
MeSH terms
Adipose Tissue, Diabetes Mellitus, Fatty Acids, Nonesterified, Humans, Insulin Resistance, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation. https://app.cochat.ai/papers/10.2337/db11-0425
The paper
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011). Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation. Diabetes. https://doi.org/10.2337/db11-0425

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.